Boryeong Signs Agreement With Sanofi To Acquire Breast Cancer Treatment Taksotel Global Business

Sep 30, 2025

Boryeong Signs Agreement With Sanofi To Acquire Breast Cancer Treatment Taksotel Global Business



Boryeong Co., Ltd. has signed an acquisition contract worth up to 175 million euros (about 287.8 billion won) for global businesses, including domestic and foreign copyrights, distribution rights, licensing rights, production rights, and trademark rights of Sanofi and the cytotoxic anticancer drug 'Taxotel (component name: Docetaxel). EUR 161 million will be paid at the closing date of the transaction and EUR 14 million will be paid when the terms set in the contract are met.

With the deal, Boryeong will take over Taksotel's entire business in 19 countries, including Korea, China, Germany and Spain, as well as in South America and the Middle East. After completing the licensing process in the future, Taksotel will be produced at Boryeong Yesan Campus, and Boryeong will directly distribute and sell original drugs in the global market.

Docetaxel is an ingredient listed on the WHO Essential Medicines List, and Taksotel is the original product of Docetaxel. Taksotel is a typical cytotoxic anticancer drug that has been widely used to treat various solid cancers such as breast cancer, prostate cancer, stomach cancer, and head and neck cancer since it was approved by the U.S. FDA in 1995. In recent years, the use of combination therapy has expanded and is playing a key role in global chemotherapy. According to Sanofi, last year, Taksotel recorded sales of 70 million euros and about 115.4 billion won in our money around the world.




Boryeong has successfully performed stable supply and conversion of its production by acquiring all domestic businesses of global original anticancer drugs such as Gemza in 2021 and Alimita in 2023. This time, it is evaluated that by acquiring the global business for the first time, it has provided an important turning point for the leap into a global pharmaceutical company beyond the scope of the business that was limited to Korea.

Boryeong plans to establish itself as a global pharmaceutical company in the field of cytotoxic anticancer drugs through the acquisition of Taksotel Business.

An official from Boryeong said, `Cytopotoxic anticancer drugs are still an essential foundation for anticancer treatment in the recent development of the anticancer treatment paradigm centered on target and immune anticancer drugs"As the actual global market has repeatedly been out of stock and supply disruptions of cytotoxic anticancer drugs, affecting patient treatment, Boryeong plans to expand its differentiated portfolio in the field of cytotoxic anticancer drugs by stably establishing a global supply chain for essential drugs that have become more important through the acquisition of Taksotel Global Business."




CEO Kim Jung-kyun of Boryeong said, "Boryeong has secured sustainable competitiveness through internalization and improvement of formulation, not just acquisition of anticancer drugs"This acquisition of Taksotel Global Business will not only be the third acquisition of anticancer drugs after Gemza and Alimita, but will also serve as an opportunity for Boryeong to secure global business rights for the first time to enter overseas markets in earnest." "Boryeong will develop the therapeutic value of 'Taxotel' by expanding to the entire R&D, including the development of follow-up formulations, combination strategies, and research on new indications, beyond simple technology transfer.""We will build a differentiated portfolio in the field of cytotoxic anticancer drugs, produce and distribute original anticancer drugs directly on the global stage, and strengthen future growth engines."," he stressed.

Reporter Kim So-hyung compact@sportschosun.com






This article was translated by Naver AI translator.